EVENTS | VIEW CALENDAR
GSK, AFFiRiS ink $553 million Alzheimer’s vaccine deal
VIENNA—British drug maker GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced in late October a collaboration agreement that grants GSK exclusive rights to AFFiRiS' Alzheimer's disease vaccine programs, aimed at treating Alzheimer's by targeting beta-amyloid. As part of the agreement, GSK is acquiring exclusive rights to develop and commercialize two Alzheimer's disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development.
AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer's disease vaccine candidates which are in preclinical development.
"We are impressed with the AFFiRiS technology—combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease," says Jean Stephenne, president and GM of GlaxoSmithKline Biologicals.
Under the terms of the agreement, AFFiRiS will receive an up-front payment of E22.5 million and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach E430 million in the event of full commercial success of the candidate vaccines. The agreement is subject to governmental authority approval.
Central to the deal is the AFFiRiS AFFiTOPE technology, which allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing, "rogue" human proteins such
as beta-amyloid, which is central to the pathology of Alzheimer's disease. DDN